Sandoz Group AG Announces Key Developments
Sandoz Group AG, a leading pharmaceutical company, has made several announcements in recent days.
- The company has launched its generic version of rivaroxaban, an antithrombotic treatment option, in Germany.
- This launch expands access to affordable treatment options for patients in the country.
Pricing Advantage for Rivaroxaban
Sandoz has announced a list price advantage across all three strengths of the medication, making it a more attractive alternative to the reference product Xarelto.
Investment in Boucherville Plant
The company has welcomed the Quebec government’s support for its Boucherville plant modernization project, which will involve a total investment of CAD 220 million. This investment will enable Sandoz to maintain its long-term supply agreement with Delpharm and continue to provide high-quality medicines to patients globally.
